Biomeditsina va amaliyot jurnali, 2022 №6

Тема статьи



Khalilova Z. Dilovar, Khaydarova A. Feruza, Alieva V. Anna


Republican Specialized Scientific-and-Practical Medical Centre of Endocrinology


Background. The COVID-19 pandemic has shown that people with non-communicable chronic diseases, in particular diabetes mellitus, are the most vulnerable to viral infection. It is of practical interest to search for risk factors for adverse outcomes of COVID-19 in patients with diabetes mellitus. Aim: Integral assessment of risk factors for death due to COVID-19. Materials and methods. A retrospective analysis of the features of the clinical course of COVID-19 depending on the presence or absence of DM was carried out on the basis of data from 5123 patients after a confirmed infection with SARS-CoV-2. Results and discussion. The presence of diabetes mellitus significantly increased the risk of death by 4.33 times, the male gender was 3.70 times more at risk of death due to coronavirus infection, the presence of obesity increased the risk of death by 2.99 times, the presence of coronary artery disease - by 5.63 times, the presence of hypertension - 1.85 times, the need for the use of glucocorticoids - understandably, occurred more often in patients with a severe course of a viral infection, so the risk of death in such patients was 1.48 times higher. More than 5 years of experience increased the risk of death by 3.91 times. It should be noted that among the dead there were no patients with diabetes experience less than 1 year. Male sex was also a significant risk factor for patients with type 2 diabetes with a RR of death of 5.03. The presence of coronary artery disease increased the risk of death due to coronavirus infection by 4.2 times among patients with type 2 diabetes. However, with regard to weight, its contribution to the increased risk of death among patients with type 2 diabetes was not significant. Also, the presence of hypertension in patients with type 2 diabetes did not increase the risk of death due to COVID-19, in contrast to the general population. In the case of patients with type 2 diabetes, the use of glucocorticoids, on the contrary, was protective - the RR of death was 2.9 times higher in those patients who did not receive glucocorticoids.

Ключевые слова

diabetes mellitus, risk of lethal outcomes, COVID-1


Sattar N, Wareham NJ, Young B, Valabhji J. Type 1 and type 2 diabetes and COVID-19 related mortality in England: a whole population study. Available from: Diabetes-Paper-2-Full-Manuscript.pdf 2. Barron E., Bakhai Ch., Kar P., Weaver A., Bradley D., Ismail H., Knighton P., Holman N., Khunti K., Sattar N., Wareham N.J., Young B., Valabhji J. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Vol 8 October 2020 813-822 doi:10.1016/S2213- 8587(20)30272-2 3. Guo W., Li M. , Dong Y., Zhou H., Zhang Z., Tian C. , et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev (2020), Article e3319, 10.1002/dmrr.3319 4. Li B., Yang J., Zhao F., Zhi L., Wang X., Liu L. , et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol (2020), 10.1007/s00392-020- 01626-9 5. Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. (2020), 10.1001/jama.2020.2648 6. Zhou F., Yu T., Du R. , Fan G., Liu Y., Liu Z., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet., 395 (2020), pp. 1054-1062, 10.1016/s0140-6736(20)30566-3 7. Hajibeygi, R., Mirghazanfari, S. M., Pahlavani, N., Jalil, A. T., Alshahrani, S. H., Rizaev, J. A., ... & Yekta, N. H. (2022). Effect of a diet based on Iranian traditional medicine on inflammatory markers and clinical outcomes in COVID-19 patients: A double-blind, randomized, controlled trial. European Journal of Integrative Medicine, 102179. 8. Зейнитдинова, З. А., РИЗАЕВ, Ж. А., & Орипов, Ф. С. (2022). Степень цитологического поражения эпителия слизистой оболочки щеки при COVID-19. ЖУРНАЛ БИОМЕДИЦИНЫ И ПРАКТИКИ, 7(2). 9. Umirzakov Zokir, Rizaev Jasur, UMIROV Safar. The phenomenon of the epidemic 10. covid-19 process and their leading determinants. Journal of Biomedicine and Practice. 2021, vol. 6, issue 6, pp. 286-295 11. Ризаев, ж. А., Кушаков, Б. Ж., Рустамова, Д. А. (2022). Проявления коронавирусной инфекции SARS-COV-2 в полости рта. Журнал биомедицины и практики, 7(2). 12. Умирзаков, З., Ризаев, Ж., Умиров, С., & Рустамова, Д. (2022). ОРГАНИЗАЦИЯ МЕДИЦИНСКИХ УСЛУГ В ЭПИДЕМИЧЕСКОМ ЦЕНТРЕ COVID-19. Журнал стоматологии и краниофациальных исследований, 2(3), 67–73.